National Jewish Health Researchers Identify BCL-2 Protein as Critical Target to Reverse Fatal Lung Scarring in Pulmonary Fibrosis

National Jewish Health researchers discover that blocking BCL-2 protein can clear scar-forming cells and restore lung function in pulmonary fibrosis models.

By: AXL Media

Published: Mar 31, 2026, 3:45 AM EDT

Source: Information for this report was sourced from National Jewish Health

Targeting the Mechanism of Persistent Lung Scarring

The progressive nature of pulmonary fibrosis, particularly idiopathic pulmonary fibrosis, has long been a medical mystery due to the resilience of scar-forming cells known as fibroblasts. In a healthy body, these cells typically dissipate after an injury has healed, but in patients with fibrosis, they persist and continue to build restrictive scar tissue. New research from National Jewish Health indicates that the protein BCL-2 is the specific mechanism allowing these cells to survive indefinitely. By uncovering this shield, scientists have identified a strategic weakness in a disease that currently has few effective treatment options and often leads to total respiratory failure.

The Role of BCL-2 in Fibroblast Survival

The study reveals that elevated levels of BCL-2 expression act as a biological safeguard, preventing fibroblasts from undergoing the natural process of programmed cell death. When these cells fail to die, they accumulate within the lung architecture, driving a continuous cycle of scarring that eventually limits oxygen intake. Senior author David Riches explains that this protein is central to the survival of these harmful cells, which sustain the disease long after the initial lung injury has occurred. By pinpointing BCL-2, the research team has moved beyond merely slowing the disease to identifying how the body might be prompted to clear the existing damage.

Linking Cellular Aging to Chronic Disease Progression

Further investigation into the behavior of these BCL-2 positive fibroblasts showed that they develop characteristics of cellular aging, a state known as senescence. This aged state contributes to the chronic nature of the disease, as senescent cells secrete signals that further degrade the surrounding lung tissue. Analyses of human lung samples confirmed that these specific, aged cells are present in patients suffering from pulmonary fibrosis, validating the findings across both laboratory and clinical environments. According to Elizabeth Redente, the first author of the study, the resistance to cell death and the development of these aged cell features are inextricably linked in the progression of the disease.